|
 |
 |
Intensified Manufacturing:
Economic models comparing steel, single use and concentrated process options
Refine Technology, LLC, in conjunction with Biopharm Services, developed two economic models to examine the cost of goods and capital requirements of cell culture production facilities configured based on different production scenarios. In this educational webcast, John Bonham-Carter, Vice President of Sales and Business Development at Refine Technology, analyzes the effect of these variables in relation to operating mode, continuous culture (perfusion) versus traditional fed batch. Click here to learn more. |
 A Brief History of Perfusion Biomanufacturing
Today's renewed interest in perfusion culture is due to an increased awareness of its advantages, some general improvement in equipment reliability, and a broadening of operational skills in the biomanufacturing industry. However some misperceptions persist. This informative paper discusses the history of perfusion and fed-batch processes, including some discussion of technological process improvements and challenges that the bioprocess industry faces. Click here to learn more.
 Meeting Increased Demands on Cell-Based Processes By Using Defined Media Supplements
As the demand for cell-derived products is rapidly increasing, there are huge pressures on the biomanufacturing industry's production capacity requirements. To keep up with this demand, more focus is being put into media development strategies for optimizing output from cell culture systems. Since traditional serum-based media poses many potential risks, more manufacturers are turning to serum-free media for protein manufacturing. Click here to learn more.
Modeling Perfusion Processes in Biopharmaceutical Production
While biopharmaceutical manufacturing is mostly batch-based, perfusion is used by a number of biomanufacturers because it produces large product quantities using smaller bioreactors than would be possible with batch-based production. Perfusion can be advantageous for less-stable products because continuous collection shortens their bioreactor residence time. This case study explores how perfusion can be used to create flexible, “just-in-time” facilities that respond to manufacturing conditions. Click here to learn more.
|
 |
 |
 |
 |
|
|
|
|
Considerations in Scale-Up of Viral Vaccine Production
BioProcess International, September 2011
Read more.
Linear Scale-Up of Cell Cultures
BioProcess International, December 2010
Read more.
An Efficient Thermoinducible Bacterial Suicide System
BioProcess International, April 2010
Read more.
I'm Losing Cell Viability and Function at Different Points in My Process, and I Don't Know Why!
BioProcess International, June 2010
Read more.
Working Toward Animal-Free Processing
BioProcess International, November 2010
Read more.
Using Disposables in Cell-Culture—Based Vaccine Production
BioProcess International, April 2010
Read more.
Improved HCP Quantitation By Minimizing Antibody Cross-Reactivity to Target Proteins
BioProcess International, January 2010
Read more.
|
|
|
|
|
|
